Kevin Patrick Danahy net worth and biography

Kevin Danahy Biography and Net Worth

CEO of Pulse Biosciences

Kevin Danahy was appointed Chief Commercial Officer in May 2024, having previously served as the Company’s President and Chief Executive Officer since September 2022. Mr. Danahy has more than 20 years of senior leadership experience building and leading strategic commercial organizations for medical technology companies. Prior to joining Pulse Biosciences, Mr. Danahy served as President of Solmetex, driving revenue growth for the company through the implementation of innovative and scalable solutions, while overseeing strategy, sales, marketing, operations, engineering, and service efforts. Previously, at Zimmer Biomet, Mr. Danahy held roles of increasing responsibility, most recently as Vice President of Global Emerging Technologies and Specialty Sales. Before his time at Zimmer, Mr. Danahy served as Senior Director at Intuitive Surgical, where he successfully transformed the sales leadership training program. Early in his career, he served in commercial leadership roles at both Medtronic and Johnson & Johnson. Mr. Danahy holds a Master’s of Science from Tufts University.

What is Kevin Patrick Danahy's net worth?: The estimated net worth of Kevin Patrick Danahy is at least $574.56 thousand as of October 2nd, 2025. Mr. Danahy owns 43,298 shares of Pulse Biosciences stock worth more than $574,564 as of December 5th. This net worth approximation does not reflect any other investments that Mr. Danahy may own. Learn More about Kevin Patrick Danahy's net worth.
How do I contact Kevin Patrick Danahy?: The corporate mailing address for Mr. Danahy and other Pulse Biosciences executives is 3957 POINT EDEN WAY, HAYWARD CA, 94545. Pulse Biosciences can also be reached via phone at (510) 906-4600 and via email at [email protected]. Learn More on Kevin Patrick Danahy's contact information.
Has Kevin Patrick Danahy been buying or selling shares of Pulse Biosciences?: During the past quarter, Kevin Patrick Danahy has sold $85,238.00 in Pulse Biosciences stock. Most recently, Kevin Patrick Danahy sold 4,600 shares of the business's stock in a transaction on Thursday, October 2nd. The shares were sold at an average price of $18.53, for a transaction totalling $85,238.00. Following the completion of the sale, the insider now directly owns 43,298 shares of the company's stock, valued at $802,311.94. Learn More on Kevin Patrick Danahy's trading history.
Who are Pulse Biosciences' active insiders?: Pulse Biosciences' insider roster includes Kevin Danahy (CEO), Robert Duggan (Co-Chairman of the Board of Directors), Mitchell Levinson (Insider), Mitchell Levinson (Insider), and Darrin Uecker (Chief Technology Officer & Director). Learn More on Pulse Biosciences' active insiders.
Are insiders buying or selling shares of Pulse Biosciences?: In the last twelve months, Pulse Biosciences insiders bought shares 3 times. They purchased a total of 145,969 shares worth more than $2,429,935.92. In the last twelve months, insiders at the sold shares 8 times. They sold a total of 160,000 shares worth more than $2,667,380.00. The most recent insider tranaction occured on October, 2nd when insider Kevin Patrick Danahy sold 4,600 shares worth more than $85,238.00. Insiders at Pulse Biosciences own 74.6% of the company. Learn More about insider trades at Pulse Biosciences.
Information on this page was last updated on 10/2/2025.

Kevin Patrick Danahy Insider Trading History at Pulse Biosciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/2/2025	Sell	4,600	$18.53	$85,238.00	43,298
9/19/2025	Sell	400	$18.48	$7,392.00	43,298
9/18/2025	Sell	20,000	$18.49	$369,800.00	43,298
11/16/2023	Buy	5,393	$6.52	$35,162.36	35,887
9/30/2022	Buy	6,500	$2.30	$14,950.00	6,500

Kevin Patrick Danahy Buying and Selling Activity at Pulse Biosciences

Pulse Biosciences Company Overview

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.

Today's Range

Now: $13.27

$13.16

$13.54

50 Day Range

MA: $16.18

$12.66

$19.94

2 Week Range

Now: $13.27

$12.56

$25.00

Volume

178,210 shs

Average Volume

171,476 shs

Market Capitalization

$899.31 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.8